Looking for the most active stocks in the S&P500 index on Thursday? Dive into today's session and discover the stocks that are dominating the trading activity and setting the pace for the market.
Eli Lilly reported positive results from Phase 3 ACHIEVE-1 trial of orforglipron for type 2 diabetes, meeting primary endpoint of A1C reduction. Analysts see potential for sales of $10 billion by 2030.
Billionaire entrepreneur Mark Cuban has expressed support for President Donald Trump's 2025 healthcare executive order, emphasizing its potential to reform the role of Pharmacy Benefit Managers (PBMs) in the U.S. healthcare system.
Wall Street has set ambitious price targets for the stocks in this article.
While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating anti-competitive practices.
Investors are running into Viking Therapeutics this week after an incident of drug-induced liver injury pushed Pfizer into terminating the development of its weight-loss pill.
Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corporation, Chevron Corporation, and Stryker Corporation, as well as two micro-cap stocks, Value Line, Inc. and Sypris Solutions, Inc.
The company said the seized counterfeit products feature lot number PAR0362 and illegitimate serial numbers beginning with the first eight digits, 51746517.
